These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8714617)

  • 41. Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis.
    Selby R; Brandwein J; O'Connor P
    Can J Neurol Sci; 1998 Nov; 25(4):295-9. PubMed ID: 9827230
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Celiac disease, Behçet, and idiopathic thrombocytopenic purpura in siblings of a patient with multiple sclerosis.
    Yamout B; Usta J; Itani S; Yaghi S
    Mult Scler; 2009 Nov; 15(11):1368-71. PubMed ID: 19825890
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Histological examination of the extrabulbar segment of the optic nerve in experimental animals after administration of Cladribine.
    Kwietniewska M; Stelmasiak Z; Sekita-Krzak J; Visconti J; Czerny K
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):222-6. PubMed ID: 12898843
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.
    Frohman EM; Havrdova E; Lublin F; Barkhof F; Achiron A; Sharief MK; Stuve O; Racke MK; Steinman L; Weiner H; Olek M; Zivadinov R; Corboy J; Raine C; Cutter G; Richert J; Filippi M
    Arch Neurol; 2006 Apr; 63(4):614-9. PubMed ID: 16606781
    [No Abstract]   [Full Text] [Related]  

  • 45. [Experiences with immunosuppressive treatment of multiple sclerosis].
    Wieczorek V; Lehnert W; Brodkorb W
    Dtsch Gesundheitsw; 1971 Sep; 26(38):1791-4. PubMed ID: 5142348
    [No Abstract]   [Full Text] [Related]  

  • 46. Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity.
    Laugel B; Borlat F; Galibert L; Vicari A; Weissert R; Chvatchko Y; Bruniquel D
    J Neuroimmunol; 2011 Dec; 240-241():52-7. PubMed ID: 22035961
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pharmacologic constraints imposed by the blood-brain barrier: the example of multiple sclerosis].
    Jolliet P
    Rev Neurol (Paris); 2000 Jul; 156(6-7):681-3. PubMed ID: 10891808
    [No Abstract]   [Full Text] [Related]  

  • 48. [Immunosuppressants and multiple sclerosis].
    Ruiz-Peña JL; Izquierdo-Ayuso G
    Rev Neurol; 2002 Aug 16-31; 35(4):373-80. PubMed ID: 12235571
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Current studies of the effects of immunosuppressive agents on multiple sclerosis].
    Minderhoud JM
    Ned Tijdschr Geneeskd; 1989 Jan; 133(3):99-100. PubMed ID: 2646546
    [No Abstract]   [Full Text] [Related]  

  • 50. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
    Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC
    J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Blockade of chemokine signaling in patients with multiple sclerosis.
    Zipp F; Hartung HP; Hillert J; Schimrigk S; Trebst C; Stangel M; Infante-Duarte C; Jakobs P; Wolf C; Sandbrink R; Pohl C; Filippi M;
    Neurology; 2006 Nov; 67(10):1880-3. PubMed ID: 17130431
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medicinal Chemistry of Multiple Sclerosis: Focus on Cladribine.
    Biernacki T; Sandi D; Bencsik K; Vécsei L
    Mini Rev Med Chem; 2020; 20(4):269-285. PubMed ID: 31644403
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Relations among multiple sclerosis, Hodgkin's disease and idiopathic thrombocytopenic purpura. Letter].
    Madrid Madrid A; Uclés A; González-Marcos JR; Gil-Peralta A
    Neurologia; 1997 Feb; 12(2):96-7. PubMed ID: 9147461
    [No Abstract]   [Full Text] [Related]  

  • 54. A comparison of two neurologic scoring instruments for multiple sclerosis.
    Koziol JA; Frutos A; Sipe JC; Romine JS; Beutler E
    J Neurol; 1996 Mar; 243(3):209-13. PubMed ID: 8936349
    [TBL] [Abstract][Full Text] [Related]  

  • 55. I've just been diagnosed with multiple sclerosis, an autoimmune disease. What can you tell me about these diseases?
    Duke Med Health News; 2010 Jan; 16(1):8. PubMed ID: 20151476
    [No Abstract]   [Full Text] [Related]  

  • 56. Ascorbic acid for the treatment of autoimmune thrombocytopenic purpura.
    Chistolini A; Mazzucconi G; De Sanctis V; Dragoni F; Mandelli F
    Haematologica; 1992; 77(2):187-8. PubMed ID: 1398308
    [No Abstract]   [Full Text] [Related]  

  • 57. Management of chronic idiopathic thrombocytopenic purpura.
    Weinrach RS
    Ariz Med; 1970 Apr; 27(4):72-5. PubMed ID: 5464053
    [No Abstract]   [Full Text] [Related]  

  • 58. No response to cladribine in five patients with chronic cold agglutinin disease.
    Berentsen S; Tjønnfjord GE; Shammas FV; Bergheim J; Hammerstrøm J; Langholm R; Ulvestad E
    Eur J Haematol; 2000 Jul; 65(1):88-90. PubMed ID: 10914950
    [No Abstract]   [Full Text] [Related]  

  • 59. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
    Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
    Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
    Schönfelder K; Schuh H; Pfister F; Krämer J; Eisenberger U; Skuljec J; Hackert J; Ruck T; Pfeuffer S; Fleischer M; Gäckler A; Hagenacker T; Kribben A; Meuth SG; Kleinschnitz C; Pul R
    Mult Scler; 2021 Oct; 27(12):1960-1964. PubMed ID: 34165361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.